Log in
Enquire now
‌

US Patent 10059762 Anti-EGFR activatable antibodies

Patent 10059762 was granted and assigned to CytomX Therapeutics on August, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
CytomX Therapeutics
CytomX Therapeutics
Current Assignee
CytomX Therapeutics
CytomX Therapeutics
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10059762
Date of Patent
August 28, 2018
Patent Application Number
15140944
Date Filed
April 28, 2016
Patent Citations Received
‌
US Patent 12091442 Activatable cytokine constructs and related compositions and methods
0
‌
US Patent 11472875 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
‌
US Patent 11981716 Activatable interleukin-2 polypeptides and methods of use thereof
0
0
‌
US Patent 11472889 Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
‌
US Patent 11535658 Activatable interleukin-2 polypeptides and methods of use thereof
‌
US Patent 11548944 Matrix metalloprotease-cleavable and serine protease-cleavable substrates and methods of use thereof
‌
US Patent 10696723 Activatable interleukin 12 polypeptides
...
Patent Primary Examiner
‌
Elly-Gerald Stoica
Patent abstract

The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolyzed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolyzing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10059762 Anti-EGFR activatable antibodies

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.